← Back to Search

Histone Deacetylase Inhibitor

Panobinostat for Rhabdoid Tumor (NORTH Trial)

Phase 2
Waitlist Available
Research Sponsored by Australian & New Zealand Children's Haematology/Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.

Eligible Conditions
  • Rhabdoid Tumor
  • Atypical Teratoid/Rhabdoid Tumor
  • Malignant Rhabdoid Tumor
  • Pediatric Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2012 Phase 3 trial • 41 Patients • NCT01034163
88%
Diarrhoea
58%
Nausea
46%
Vomiting
35%
Fatigue
27%
Neutropenia
27%
Thrombocytopenia
27%
Oropharyngeal pain
23%
Headache
19%
Upper respiratory tract infection
19%
Nasopharyngitis
15%
Sinusitis
15%
Influenza like illness
15%
Pyrexia
15%
Decreased appetite
12%
Leukopenia
12%
Muscle spasms
12%
Depression
12%
Arthralgia
12%
Cough
12%
Dysgeusia
12%
Gastrooesophageal reflux disease
12%
Asthenia
8%
Urinary tract infection
8%
Mucosal dryness
8%
Herpes virus infection
8%
Back pain
8%
Polyneuropathy
8%
Paranasal sinus hypersecretion
8%
Abdominal pain upper
8%
Constipation
8%
Platelet count decreased
4%
Cellulitis
4%
Gastroenteritis salmonella
4%
Sinusitis bacterial
4%
Insomnia
4%
Non-cardiac chest pain
4%
Hypophosphataemia
4%
Pruritus
4%
Abdominal pain
4%
Chills
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Panobinostat (PAN)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Osteosarcoma [arm closed]Experimental Treatment1 Intervention
Group II: Neuroblastoma [arm closed]Experimental Treatment1 Intervention
Group III: Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid TumorExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panobinostat
2011
Completed Phase 3
~1560

Find a Location

Who is running the clinical trial?

Australian & New Zealand Children's Haematology/Oncology GroupLead Sponsor
6 Previous Clinical Trials
6,882 Total Patients Enrolled
National Health and Medical Research Council, AustraliaOTHER
166 Previous Clinical Trials
476,852 Total Patients Enrolled
Secura Bio, Inc.Industry Sponsor
8 Previous Clinical Trials
194 Total Patients Enrolled
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top